Alongside the NeoGenomics and Labcorp deals, this year has seen several other large-scale diagnostic company acquisitions.

On 15 March, Roche announced a definitive agreement to fully acquire GenMark for $24.05 per share in cash for all of GenMark’s common stock. The deal price represents a 43% premium over GenMark’s closing share price on 10 February, which was the last trading day before Bloomberg reported that GenMark was exploring a sale. The merger agreement has been unanimously approved by the boards of directors of GenMark and Roche. The companies expect the transaction to close in the second quarter of 2021. Roche is based in Basel, Switzerland, but GenMark’s principal operations will continue in Carlsbad, CA.
Also on 15 March, Veracyte acquired Decipher for $600m in cash, the companies announced on 15 March. San Diego-based Decipher will be a wholly owned subsidiary of South San Francisco-based Veracyte. The total revenue for Decipher and Veracyte in 2020, combined, was about $186m, according to Decipher, which recorded revenue of around $39m in 2020 and sold about 16,000 genomic tests. Decipher’s prostate test system includes a prostate biopsy genomic classifier test and a post-surgery prognosis test that predict a patient’s risk of metastasis within five years. It is designed to help guide the selection of appropriate therapies for each patient.
On 8 April, Hologic announced it was buying Finland-based molecular diagnostic company Mobidiag for $785m to take advantage of the fast-growing acute care market. This deal is Hologic’s fourth major acquisition this year so far.
On 13 April, Italian diagnostics company DiaSorin agreed to buy Luminex for about $1.8bn in an all-cash transaction. DiaSorin said on 11 April the acquisition of Austin, TX-based Luminex, which makes COVID-19 testing kits among other tests, will broaden DiaSorin’s positioning in the molecular diagnostics space and its presence in the US.
On 17 May, PerkinElmer announced it had acquired UK-based Immunodiagnostics Systems Holdings PLC for about $155m in cash. PerkinElmer said the transaction has a total enterprise value of about $124m and expects it to close in the third quarter of 2021. The deal will allow PerkinElmer to grow its overall diagnostics business and specifically its immunodiagnostics segment and combine its channel expertise and testing capabilities with Immunodiagnostics’ chemiluminescence products in endocrinology, autoimmunity, and infectious diseases.

Big Money Spent On Liquid Biopsy Technology In 2021

More from Deals

More from Business